publication . Article . 2010

Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases

David B. Ridley; Alfonso Calles Sánchez;
Open Access
  • Published: 13 Sep 2010
Every year 1 billion people worldwide are affected by traditionally neglected diseases, such as malaria, tuberculosis, leishmaniasis, and lymphatic filariasis, which impose tremendous public health burdens. Governments, foundations, and drug manufacturers have, however, started to support development of new treatments. European Union Member States have been leaders in implementing so-called push mechanisms (payment for drug development) and pull funding (reward for output), such as the advance market commitment, which creates a market for vaccines by guaranteeing prices. We propose an additional step that could be taken to encourage development of medicines for ...
Persistent Identifiers
Medical Subject Headings: health care economics and organizations
free text keywords: General Medicine, European union, media_common.cataloged_instance, media_common, Economic growth, Voucher, Payment, media_common.quotation_subject, Priority review, Antiparasitic agent, Orphan Drug Production, Public health, medicine.medical_specialty, medicine, Reimbursement, business.industry, business
Download fromView all 2 versions
Open Access
The Lancet
Provider: UnpayWall
Open Access
Article . 2010
Provider: ZENODO
The Lancet
Article . 2010
Provider: Crossref
Any information missing or wrong?Report an Issue